Suven gets 3 European patents on NCEs

01 Dec 2009 Evaluate

Suven Life Sciences Limited, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, has received patents corresponding to three new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.

 

The patents, valid up to 2022, 2023 and 2024 respectively, were granted by the European Patent Office (EPO). With these new patents, Suven now has 7 granted EPO patents on NCEs, which have been validated in the 37 member countries in Europe.

 

The newly granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-generative disorders like Alzheimer’s, Parkinson, schizophrenia, Huntington’s disease and attention-deficit hyperactivity disorder (ADHD). Suven Life currently has six internally-discovered therapeutic drug candidates, which are in pre-clinical stage of development targeting conditions such as  ADHD, dementia, depression and Huntington’s disease.

crackcrack

Suven Life Sciences Share Price

153.15 -6.60 (-4.13%)
12-Jan-2026 09:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.20
Dr. Reddys Lab 1202.80
Cipla 1450.20
Zydus Lifesciences 882.75
Lupin 2144.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×